GoodRx has emerged as a meaningful pricing channel for branded and oral GLP-1 drugs. The platform's 2026 expansion of oral semaglutide pricing-match programs put pressure on direct-to-consumer pricing across the category.
Key 2026 stories: GoodRx matching oral semaglutide pricing in the post-launch competitive frame, Novo's Ozempic-pill channel expansion through GoodRx and WW Med+, and the broader retail-pharmacy economics of GLP-1 self-pay.
Stories here cover the pricing moves and the retail-pharmacy competitive dynamics. See #pricing and #telehealth for related threads.
GoodRx announced May 1 that it has added self-pay access for the Ozempic pill, offering eligible patients with type 2 diabetes the medication at $149/month for the 1.5 mg dose, $199/month for 4 mg, and $299/month for 9 mg at participating pharmacies nationwide. The collaboration extends GoodRx's existing work across Novo Nordisk's full semaglutide portfolio, letting cash-paying patients bypass insurance complexity at the counter. The launch closes a transparency gap that has dogged consumer access to oral GLP-1 therapy.
An April 22 NPR report citing GoodRx research found that 12 million people each lost insurance coverage for Wegovy and Zepbound between 2025 and 2026, while 88% of those still covered face restrictions like prior authorization or BMI 40+ requirements. About 60% of GLP-1 users now pay out of pocket — often hundreds of dollars monthly — reframing the affordability debate after the BALANCE model's cancellation.
GoodRx announced oral semaglutide availability via its telemedicine platform at $149 for lower doses, matching Novo Nordisk pricing and intensifying the GLP-1 price war.